Clinical Trials on Oligometastatic Prostate Carcinoma in United States

Total 14063 results

Mayo Clinic

Recruiting

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer

Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
University of Florida

Completed

Radiotherapy for Oligometastatic Prostate Cancer

Oligometastatic Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
POINT Biopharma

Active, not recruiting

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (LUNAR)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer (NRG PROMETHEAN)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States, Canada
Mayo Clinic

Recruiting

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Biochemically Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate Adenocarcinoma

United States
Mayo Clinic

Not yet recruiting

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
Catherine Spina
Arcus Biosciences, Inc.

Recruiting

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer (SBRT-AMICO)

Oligometastatic Prostate Cancer

United States
VA Office of Research and Development

Completed

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Newly Diagnosed Oligometastatic Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Prostate Cancer | Oligometastatic Disease | Castrate Sensitive Prostate Cancer

United States
University of Maryland, Baltimore

Recruiting

TERPS Trial for de Novo Oligometastic Prostate Cancer

Prostate Cancer | Oligometastatic Disease

United States
Novartis Pharmaceuticals

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (PSMA-DC)

Oligometastatic Prostate Cancer (OMPC)

Japan, Singapore, Canada, Israel, Switzerland, Australia, United States
University of Maryland, Baltimore
Janssen Scientific Affairs, LLC

Recruiting

High-Risk Metachronous Oligometastatic Prostate Cancer Trial (KNIGHTS)

Prostate Cancer | Oligometastatic Disease

United States
University of Washington
National Cancer Institute (NCI)

Completed

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate Adenocarcinoma

United States
Emory University

Completed

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Prostate Carcinoma Metastatic to the Bone

United States
University of Utah

Completed

Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Unknown

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

Prostate Adenocarcinoma | Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Mamta Parikh
National Cancer Institute (NCI); Pandomedx

Completed

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer

United States
Roswell Park Cancer Institute
Active Biotech AB

Completed

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
Novartis; Stand Up To Cancer; Prostate Cancer Foundation

Active, not recruiting

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IV Prostate Cancer AJCC v7

United States
University of Washington
Janssen Research & Development, LLC

Terminated

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Double-Negative Prostate Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Active, not recruiting

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (PROMOTE)

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer

United States
OHSU Knight Cancer Institute
United States Department of Defense; Oregon Health and Science University

Completed

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (DEXTER)

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
VA Office of Research and Development

Recruiting

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT)

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Oligometastasis | Oligorecurrence | De Novo Prostate Cancer

United States
University of Washington

Recruiting

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Mayo Clinic

Completed

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Mamta Parikh
National Cancer Institute (NCI)

Recruiting

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer

United States
OHSU Knight Cancer Institute
Janssen Scientific Affairs, LLC; Oregon Health and Science University

Active, not recruiting

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
Jonsson Comprehensive Cancer Center

Completed

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | PSA Level Greater Than Fifty

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Terminated

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Stanford University
National Cancer Institute (NCI)

Completed

68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

Recurrent Prostate Carcinoma

United States
Andrei Iagaru

Completed

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | PSA Failure

United States
Roswell Park Cancer Institute

Recruiting

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center

Completed

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma

United States
Jonsson Comprehensive Cancer Center

Completed

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery (PSMA vs AXUMIN)

Recurrent Prostate Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage III Prostate Cancer AJCC v8 | Advanced Prostate Carcinoma

United States
Northwestern University

Recruiting

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic Cancer

United States
University of California, San Francisco
National Cancer Institute (NCI)

Terminated

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States

Clinical Trials on Oligometastatic Prostate Carcinoma in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations